Evidence map›Paper›PMID 27375020›Full record

ArticleOncogene2017

Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition.

Q Zhang, S Liu, K R Parajuli, W Zhang, K Zhang, Z Mo, J Liu, Z Chen, S Yang, A R Wang and 2 more

Open access · greenAbstract read
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

121 citing papers in PubMed, 1 synthesis or guideline pooled it, 203 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. [Scutellarin improves metabolic dysfunction-associated steatotic liver disease in rats by regulating MMP7 and LCN2].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

61 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Q ZhangDepartment of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, LA, USA.
S LiuDepartment of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, LA, USA.
K R ParajuliDepartment of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, LA, USA.
W ZhangDepartment of Computer Science and Biostatistics Facility of RCMI Cancer Research Center, Xavier University of Louisiana, New Orleans, LA, USA.
K ZhangDepartment of Computer Science and Biostatistics Facility of RCMI Cancer Research Center, Xavier University of Louisiana, New Orleans, LA, USA.
Z MoDepartment of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, LA, USA.
J LiuDepartment of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, LA, USA.
Z ChenDepartment of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, LA, USA.
S YangDepartment of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, LA, USA.
A R WangDepartment of Pathology and Laboratory Medicine, Tulane University, New Orleans, LA, USA.
L MyersDepartment of Biostatistics and Bioinformatics, Tulane University, New Orleans, LA, USA.
Z YouDepartment of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, LA, USA.ORCID 0000-0001-5048-2229
Tulane University · USXavier University of Louisiana · USHebei Medical University · CN

Funding

UNCOVERING THE MECHANISMS OF OSTEOSARCOMA METASTASIS SUPPRESSION BY MTBPP20RR020152 · NCRR · TULANE UNIVERSITY OF LOUISIANA · PI YOU, ZONGBING · 2004 to 2011
$17.0M
Xavier's RCMI Cancer Research ProgramG12MD007595 · NIMHD · XAVIER UNIVERSITY OF LOUISIANA · PI D'AMOUR, GENE, WANG, GUANGDI · 2012 to 2018
$15.7M
Mentoring a Cancer Genetics ProgramP20GM103518 · NIGMS · TULANE UNIVERSITY OF LOUISIANA · PI DEININGER, PRESCOTT L. · 2012 to 2013
$4.3M
The role of IL-17 in prostate cancerR01CA174714 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI YOU, ZONGBING · 2013 to 2017
$1.6M
NCI NIH HHS R01 CA174714NCRR NIH HHS P20 RR020152NIGMS NIH HHS P20 GM103518NIMHD NIH HHS G12 MD007595
6 · The paper itself

Abstract

Chronic inflammation has been associated with a variety of human cancers including prostate cancer. Interleukin-17 (IL-17) is a critical pro-inflammatory cytokine, which has been demonstrated to promote development of prostate cancer, colon cancer, skin cancer, breast cancer, lung cancer and pancreas cancer. IL-17 promotes prostate adenocarcinoma with a concurrent increase of matrix metalloproteinase 7 (MMP7) expression in mouse prostate. Whether MMP7 mediates IL-17's action and the underlying mechanisms remain unknown. We generated Mmp7 and Pten double knockout (KO) (Mmp7

Indexed as

AnimalsCell Line, TumorEpithelial-Mesenchymal TransitionHumansInflammationInterleukin-17MaleMatrix Metalloproteinase 7MiceProstatic NeoplasmsSignal TransductionInterleukin-17Matrix Metalloproteinase 7

Identifiers

PMID27375020
PMCPMC5213194
OpenAlexW2470213520

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.